Analysts See 12% Upside To Thermo Fisher Scientific Inc. (TMO)

Thermo Fisher Scientific Inc. (NYSE:TMO) is among the 14 Best S&P 500 Stocks to Buy Now. As of the close of business on December 17, Wall Street analysts have a consensus Strong Buy rating on the stock, with a one-year average share price target of $640.30, representing an upside of 12%.

Analysts See 12% Upside To Thermo Fisher Scientific Inc. (TMO)

Recent analyst updates include Wells Fargo lifting its price target on the stock to $675 from $635 on December 15, citing increased clarity about the U.S. government’s policies on the pharmaceutical industry, coupled with future growth projections suggesting an upside.

The firm believes the situation is ripe for companies selling tools and equipment, and has kept its Overweight rating on the stock.

This followed Citigroup’s update on Thermo Fisher Scientific Inc. (NYSE:TMO) on December 11, when it upgraded the stock’s rating to Buy from Neutral and hiked its price target to $660 from $580.

The revision by Citi analyst Patrick Donnelly was part of the firm’s broader analysis for stocks in the tools and diagnostics segment heading into 2026. The firm believes ongoing onshoring trends and increased pharmaceutical spending will benefit the company.

Thermo Fisher Scientific Inc. (NYSE:TMO) is a leading provider of life sciences solutions, laboratory products, diagnostics, analytical instruments, and biopharma services. The stock has had modest returns in 2025, gaining 8% year-to-date.

While we acknowledge the risk and potential of TMO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than TMO and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 11 Most Oversold S&P 500 Stocks Heading into 2026 and Top 15 Lowest P/E Ratios of the S&P 500 in 2025.

Disclosure: None.